Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive Treatment for MRD+ MDS/AML Post-SCT
NCT05788679Phase 2Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Karolinska University Hospital. Started Nov 2022; status: recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05788679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788679.